Category: Biosciences

  • Janssen Acquires Rights to Hemera’s HMR59 for Late-Stage Age-Related Macular Degeneration

    Shots: Janssen acquires rights to Hemera’s HMR59, administered as a one-time, outpatient, IVT inj. to help preserve vision in patients with geographic atrophy The acquisition will boost Janssen’s eye disease portfolio & strengthens its gene therapy capabilities HMR59 is designed to increase the ability of retina cells to make a soluble form of CD59, helping […]